Related Experiment Video
Updated: Jul 3, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
An antimetastatic role for decorin in breast cancer
Silvia Goldoni1, Daniela G Seidler, Jack Heath
1Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract:
Decorin, a member of the small leucine-rich proteoglycan gene family, down-regulates members of the ErbB receptor tyrosine kinase family and attenuates their signaling, leading to growth inhibition. We investigated the effects of decorin on the growth of ErbB2-overexpressing mammary carcinoma cells in comparison with AG879, an established ErbB2 kinase inhibitor. Cell proliferation and anchorage-independent growth assays showed that decorin was a potent inhibitor of breast cancer cell growth and a pro-apoptotic agent. When decorin and AG879 were used in combination, the inhibitory effect was synergistic in proliferation assays but only additive in both colony formation and apoptosis assays. Active recombinant human decorin protein core, AG879, or a combination of both was administered systemically to mice bearing orthotopic mammary carcinoma xenografts. Primary tumor growth and metabolism were reduced by approximately 50% by both decorin and AG879. However, no synergism was observed in vivo. Decorin specifically targeted the tumor cells and caused a significant reduction of ErbB2 levels in the tumor xenografts. Most importantly, systemic delivery of decorin prevented metastatic spreading to the lungs, as detected by novel species-specific DNA detection and quantitative assays. In contrast, AG879 failed to have any effect. Our data support a role for decorin as a powerful and effective therapeutic agent against breast cancer due to its inhibition of both primary tumor growth and metastatic spreading.
Insights
Decorin effectively inhibits breast cancer cell growth and metastasis. This small leucine-rich proteoglycan shows therapeutic potential by reducing primary tumor growth and preventing lung metastasis, unlike the ErbB2 inhibitor AG879.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Decorin is a small leucine-rich proteoglycan that negatively regulates ErbB receptor tyrosine kinase signaling.
- ErbB2 overexpression is implicated in mammary carcinoma progression and metastasis.
Purpose of the Study:
- To investigate the therapeutic potential of decorin against ErbB2-overexpressing breast cancer.
- To compare the efficacy of decorin with AG879, an ErbB2 kinase inhibitor, in preclinical models.
Main Methods:
- In vitro cell proliferation, anchorage-independent growth, and apoptosis assays.
- In vivo studies using orthotopic mammary carcinoma xenografts in mice.
- Systemic administration of decorin and AG879, individually and in combination.
- Assessment of primary tumor growth, metabolism, ErbB2 levels, and lung metastasis using species-specific DNA detection.
Main Results:
- Decorin significantly inhibited breast cancer cell proliferation and induced apoptosis in vitro.
- Both decorin and AG879 reduced primary tumor growth and metabolism by approximately 50% in vivo, with no observed synergism.
- Decorin specifically reduced ErbB2 levels in tumors and, crucially, prevented lung metastasis.
- AG879 demonstrated no effect on metastasis.
Conclusions:
- Decorin is a potent inhibitor of breast cancer growth and metastasis.
- Decorin exhibits a dual therapeutic effect by targeting primary tumor growth and preventing metastatic spread.
- Decorin represents a promising therapeutic agent for breast cancer, particularly in cases of ErbB2 overexpression.
Related Concept Videos
The Tumor Microenvironment
Role of Matrix Metalloproteases in Degradation of ECM
A...
